Expanded OptiVision Presbyopia Reversal Trial On SurgiLight’s Horizon
This article was originally published in The Gray Sheet
Executive Summary
SurgiLight will need additional funding to support expansion of its IDE trial for the OptiVision presbyopia reversal system, following a lawsuit filed by Merrill Lynch over its credit line
You may also be interested in...
SurgiLight secures funding
Ophthalmic laser firm seals $500,000 private placement with accredited investor group Jan. 24. The firm will use the proceeds to expand a U.S. trial of its OptiVision presbyopia system and repay a credit line requested by Merrill Lynch in a Jan. 6 lawsuit (1"The Gray Sheet" Jan. 13, 2003, p. 19)...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.